Fairmount Funds Management LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Fairmount Funds Management LLC reported 17 stock positions worth $1.0 billion. Its top holding was Axsome Therapeutics (AXSM) at 12.4% of the portfolio, followed by Nuvalent Class A (NUVL, 10.3%) and Spyre Therapeutics (SYRE, 9.3%). Compared with Q3 2024, it opened 3 new positions, sold out of 1, added to 1 and reduced 3. The biggest buy was a new position in Scholar Rock (SRRK) and the biggest sale Axsome Therapeutics (AXSM, shares −38%).
- Most Recent 13F
- Q2 2026
- Location
- WEST CONSHOHOCKEN, PA
- CIK
- 0001802528
- Portfolio Value
- $1.0B (Q4 2024)
- SEC Filing
- 0001104659-25-014003 ↗ filed Feb 14, 2025
Holdings Value
Holdings 17 stocks · $1.0B
| AXSM Axsome Therapeutics Inc. | 12.36% | 1,468,983 | $124.3M | Reduce -37.8% |
| NUVL Nuvalent Inc. Class A | 10.25% | 1,317,664 | $103.1M | Reduce -21.9% |
| SYRE Spyre Therapeutics Inc. | 9.30% | 4,018,101 | $93.5M | No change |
| APGE Apogee Therapeutics Inc. | 9.23% | 2,048,647 | $92.8M | No change |
| SRRK Scholar Rock Holding Corp. | 8.43% | 1,962,953 | $84.8M | New |
| ELVN Enliven Therapeutics Inc. | 7.16% | 3,202,798 | $72.1M | No change |
| VRDN Viridian Therapeutics Inc. | 6.57% | 3,445,813 | $66.1M | No change |
| ORKA Oruka Therapeutics Inc. | 6.50% | 3,371,922 | $65.4M | Add +5.0% |
| DNTH Dianthus Therapeutics Inc. | 5.85% | 2,700,691 | $58.9M | No change |
| COGT Cogent Biosciences Inc. | 4.83% | 6,225,641 | $48.6M | No change |
| KNSA Kiniksa Pharmaceuticals Inte | 4.32% | 2,194,341 | $43.4M | Reduce -31.5% |
| DAWN Day One Biopharmaceuticals I | 3.91% | 3,103,448 | $39.3M | No change |
| ATXS Astria Therapeutics Inc. | 3.16% | 3,554,129 | $31.8M | No change |
| ANAB Anaptysbio Inc. | 2.39% | 1,816,466 | $24.1M | New |
| BCAX Bicara Therapeutics Inc. | 2.22% | 1,284,169 | $22.4M | No change |
| IKT Inhibikase Therapeutics Inc. | 1.98% | 6,125,000 | $19.9M | New |
| ZBIO Zenas Biopharma Inc. | 1.54% | 1,892,806 | $15.5M | No change |
Portfolio Sells Q3 2024 → Q4 2024
Portfolio Buys Q3 2024 → Q4 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.5B | ORKA, DNTH, DMRA, COGT, JBIO |
| Q1 2026 | 12 | $1.4B | DMRA, DNTH, COGT, SYRE, ORKA |
| Q4 2025 | 13 | $1.3B | COGT, APGE, SYRE, VRDN, ORKA |
| Q3 2025 | 17 | $1.1B | DNTH, COGT, AXSM, APGE, ELVN |
| Q2 2025 | 17 | $771.9M | APGE, AXSM, ELVN, SRRK, SYRE |
| Q1 2025 | 15 | $644.6M | AXSM, APGE, SYRE, ELVN, NUVL |
| Q4 2024 | 17 | $1.0B | AXSM, NUVL, SYRE, APGE, SRRK |
| Q3 2024 | 15 | $1.2B | AXSM, NUVL, APGE, SYRE, ELVN |
| Q2 2024 | 13 | $885.1M | AXSM, NUVL, SYRE, APGE, ELVN |
| Q1 2024 | 15 | $917.4M | AXSM, NUVL, APGE, DNTH, KNSA |